CN SSE

Kangmei Pharmaceutical Co., Ltd.

Chinese traditional medicine manufacturer that fabricated 30 billion yuan ($4.4B) in cash balances, later blamed by management on a 'clerical error'.

CORPORATE IDENTIFIERS & DOSSIER
  • Entity Name: Kangmei Pharmaceutical Co., Ltd.
  • Country of Domicile: CN
  • Listing & Ticker: SSE (600518).
  • CIK / LEI Identifier: Unregistered.
  • Industry Classification: Pharmaceutical Preparations (SIC 2834).
  • Cumulative Overstatement: $4.4B across 1 enforcement episode(s).
  • Assessed Penalties: $350.0M.

PRIMARY ENFORCEMENT CASES INVOLVING KANGMEI PHARMACEUTICAL CO., LTD.

1 CASE DOSSIERS
Case Title Status Primary Scheme Overstatement Total Penalties Action Date
Kangmei Pharmaceutical: 30 Billion Yuan ($4.4B) Fabricated Cash Balances Adjudicated fictitious cash and assets $4.4B $350.0M September 20, 2021

FORENSIC PROFILE: KANGMEI PHARMACEUTICAL: 30 BILLION YUAN ($4.4B) FABRICATED CASH BALANCES

FULL CASE DOSSIER →

Inflated bank cash balances by 29.9 billion yuan, fabricated 20B yuan in revenues, and overstated inventory using fake purchase vouchers before claiming the discrepancy was a 'clerical error'.

The company manipulated its accounting records by executing schemes under fictitious-cash-and-assets. Financial reports filed with market regulators contained material misstatements that distorted true financial condition.

Fraud Window: January 1, 2019 to December 31, 2021 • Primary Regulator: China Securities Regulatory Commission (CSRC) • Auditor: Ernst & Young LLP

Documented Accounting Irregularities & Regulatory Findings

  • FICTITIOUS CASH AND ASSETS: Inflated bank cash balances by 29.9 billion yuan, fabricated 20B yuan in revenues, and overstated inventory using fake purchase vouchers before claiming the discrepancy was a 'clerical error'.

Primary Public Dockets & Actions

  • [ENF-2019-kangmei-pharma] Enforcement Action: Kangmei Pharmaceutical: 30 Billion Yuan ($4.4B) Fabricated Cash Balances (September 20, 2021): Inflated bank cash balances by 29.9 billion yuan, fabricated 20B yuan in revenues, and overstated inventory using fake purchase vouchers before claiming the discrepancy was a 'clerical error'. Official Record ↗